Evidence map›Paper›PMID 41455923›Full record

ArticleBMC microbiology2025

Molecular detection and ultrastructure characterization of some drug-resistant Gram-negative bacteria isolated from bladder cancer patients.

Mohamed M A Mousa, Mohamed I Abou-Dobara, Mohamed M El-Zahed, Manal E El-Sherif, Hazem H Saleh

Abstract read
In one paragraph

Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mohamed M A MousaDepartment of Botany and Microbiology, Faculty of Science, Damietta University, New Damietta, 34517, Egypt.
Mohamed I Abou-DobaraDepartment of Botany and Microbiology, Faculty of Science, Damietta University, New Damietta, 34517, Egypt.
Mohamed M El-ZahedDepartment of Botany and Microbiology, Faculty of Science, Damietta University, New Damietta, 34517, Egypt. mohamed.marzouq91@du.edu.eg.
Manal E El-SherifDepartment of Botany and Microbiology, Faculty of Science, Damietta University, New Damietta, 34517, Egypt.
Hazem H SalehUrology and Nephrology Center, Mansoura University, Mansoura, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUrinary tract infections (UTIs) are among the most common and potentially fatal illnesses that cancer patients experience. Infections in general are a major cause of morbidity and mortality in this population. The objective of this investigation was to detect some Gram-negative bacteria recovered from different urine specimens isolated from bladder cancer patients and examine their ultrastructural characteristics.

resultsGram-negative bacteria that are resistant to carbapenems were identified and isolated. Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa were then tested for employing meropenem in the phenotypic modified Hodge test (MHT), the modified carbapenem inactivation technique (mCIM), and the combined disk test (CDT). Genotypic detection of bacterial isolates was studied using the blaNDM, blaVIM, and blaIMP carbapenemase genes. 50 isolates (K. pneumoniae, E. coli, and P. aeruginosa) were tested for plasmid-mediated carbapenemase genes. Finally, agarose gel electrophoresis was used to investigate the polymerase chain reaction of blaNDM, blaVIM, and blaIMP carbapenemase genes. The structural characteristics of E. coli, P. aeruginosa, and K. pneumoniae were analyzed using transmission electron microscopy (TEM) to observe bacterial ultrastructure and illustrate cellular changes consistent with antimicrobial resistance. Gram-negative bacterial isolates included 35 K. pneumoniae, E. coli, and P. aeruginosa recovered from the study’s different urine samples. The resistance profile of K. pneumoniae and E. coli was greater than 80% for all tested antibiotics. Amikacin also exhibited high resistance at 80% (i.e., 20% susceptibility). The resistance profile of P. aeruginosa exceeded 100% for all examined antibiotics. Notably, amikacin was the single agent to which K. pneumoniae and E. coli demonstrated any measurable susceptibility (20%), distinguishing it as the best-performing antibiotic among the tested drugs, despite its overall limited efficacy. Unfortunately, high resistance was observed for all other examined antibiotics. The obtained results of MHT, mCIM, and CDT tests revealed that 82%, 32%, and 74% of isolated bacteria were carbapenem-resistant, respectively. PCR data revealed that blaIMP is the most relevant gene, followed by blaNDM and finally blaVIM, with 36%, 32%, and 22%, respectively. The current study showed a positive result of PCR for blaNDM, blaVIM genes, and blaIMP, respectively.

conclusionsIsolates that produced carbapenemase exhibited high levels of resistance to numerous antimicrobials employed in this investigation. The study focused on the genotypic detection of blaNDM, blaVIM, and blaIMP. To obtain a thorough understanding of the existence of high-risk clones with antimicrobial resistance, carbapenemase genes containing Gram-negative isolates were necessary. The study recommends that the evaluation of the importance of bacterial resistance in human therapies would undoubtedly reap major benefits upon the use of difficult-to-treat resistance (DTR) in clinical practice and at the bedside.

Indexed as

Drug Resistance, BacterialGram-Negative BacteriaGram-Negative Bacterial InfectionsUrinary Bladder NeoplasmsUrinary Tract InfectionsAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCarbapenemsEscherichia coliHumansKlebsiella pneumoniaeMicrobial Sensitivity TestsMicroscopy, Electron, TransmissionPseudomonas aeruginosaAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemsE. coliGenotypicGram-negative bacteriaK. pneumoniaeP. aeruginosaPCRUltrastructure

Identifiers

PMID41455923
PMCPMC12849410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.